A phase I randomized, investigator and participant-blind, adaptive, multiple-ascending dose, parallel and four-way crossover, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and drug interactions (with midazolam) of RO7308480 following oral administration in healthy participants.